Adoptive immunotherapy for cancer: building on success

[1]  P. Lipsky,et al.  TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. , 2006, Blood.

[2]  C. Klebanoff,et al.  Interleukin-2-dependent mechanisms of tolerance and immunity in vivo , 2006, The Journal of Immunology.

[3]  S. Rosenberg,et al.  Modulation by IL-2 of CD70 and CD27 Expression on CD8+ T Cells: Importance for the Therapeutic Effectiveness of Cell Transfer Immunotherapy1 , 2006, The Journal of Immunology.

[4]  S. Rosenberg,et al.  Comparison of Common γ-Chain Cytokines, Interleukin-2, Interleukin-7, and Interleukin-15 for the In Vitro Generation of Human Tumor-Reactive T Lymphocytes for Adoptive Cell Transfer Therapy , 2006, Journal of immunotherapy.

[5]  Helen Y Wang,et al.  Regulatory T cells and Toll-like receptors in tumor immunity. , 2006, Seminars in immunology.

[6]  J. Sprent,et al.  Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes , 2006, Science.

[7]  S. Nutt,et al.  Transcriptional repressor Blimp-1 is essential for T cell homeostasis and self-tolerance , 2006, Nature Immunology.

[8]  K. Calame,et al.  Transcriptional repressor Blimp-1 regulates T cell homeostasis and function , 2006, Nature Immunology.

[9]  Thierry Boon,et al.  Human T cell responses against melanoma. , 2006, Annual review of immunology.

[10]  S. Ziegler,et al.  Cutting Edge: Anti-CD25 Monoclonal Antibody Injection Results in the Functional Inactivation, Not Depletion, of CD4+CD25+ T Regulatory Cells1 , 2006, The Journal of Immunology.

[11]  S. Rosenberg,et al.  IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. , 2006, Blood.

[12]  M. Cooke,et al.  Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors , 2006, Nature Medicine.

[13]  I. Pastan,et al.  Selective Elimination of Human Regulatory T Lymphocytes In Vitro With the Recombinant Immunotoxin LMB-2 , 2006, Journal of immunotherapy.

[14]  A. McMichael,et al.  Human Naive CD8 T Cells Down-Regulate Expression of the WNT Pathway Transcription Factors Lymphoid Enhancer Binding Factor 1 and Transcription Factor 7 (T Cell Factor-1) following Antigen Encounter In Vitro and In Vivo1 , 2006, The Journal of Immunology.

[15]  N. Restifo,et al.  The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumor. , 2006, Cancer research.

[16]  T. Waldmann.  Effective cancer therapy through immunomodulation. , 2006, Annual review of medicine.

[17]  C. Bordignon,et al.  Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. , 2005, Blood.

[18]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Rosenberg,et al.  Primary Human T Lymphocytes Engineered with a Codon-Optimized IL-15 Gene Resist Cytokine Withdrawal-Induced Apoptosis and Persist Long-Term in the Absence of Exogenous Cytokine1 , 2005, The Journal of Immunology.

[20]  M. Smyth,et al.  Supernatural T cells: genetic modification of T cells for cancer therapy , 2005, Nature Reviews Immunology.

[21]  E. Gilboa,et al.  Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.

[22]  S. Rosenberg,et al.  Telomere Length of Transferred Lymphocytes Correlates with In Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy1 , 2005, The Journal of Immunology.

[23]  B. Fox,et al.  Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. , 2005, Cancer research.

[24]  S. Rosenberg,et al.  Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR , 2005, The Journal of Immunology.

[25]  S. Rosenberg,et al.  Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma , 2005, Journal of immunotherapy.

[26]  R. Clark,et al.  Human skin cells support thymus-independent T cell development. , 2005, The Journal of clinical investigation.

[27]  Andrew J. McMichael,et al.  Molecular Signatures Distinguish Human Central Memory from Effector Memory CD8 T Cell Subsets1 , 2005, The Journal of Immunology.

[28]  A. Rudensky,et al.  A function for interleukin 2 in Foxp3-expressing regulatory T cells , 2005, Nature Immunology.

[29]  W. Blackwelder,et al.  Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer , 2005, Nature Medicine.

[30]  J. Berzofsky,et al.  Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells , 2005, Nature Medicine.

[31]  S. Rosenberg,et al.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells , 2005, The Journal of experimental medicine.

[32]  L. Kaer,et al.  NK cells promote islet allograft tolerance via a perforin-dependent mechanism , 2005, Nature Network Boston.

[33]  K. Akashi,et al.  Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice , 2005 .

[34]  C. Yee,et al.  IL-21 Influences the Frequency, Phenotype, and Affinity of the Antigen-Specific CD8 T Cell Response1 , 2005, The Journal of Immunology.

[35]  V. Bronte,et al.  Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.

[36]  T. Waldmann,et al.  Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S. Rosenberg,et al.  Large-Scale Depletion of CD25+ Regulatory T Cells from Patient Leukapheresis Samples , 2005, Journal of immunotherapy.

[38]  D. Speiser,et al.  Toward improved immunocompetence of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.

[39]  S. Rosenberg,et al.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.

[40]  R. Ahmed,et al.  BCL6b mediates the enhanced magnitude of the secondary response of memory CD8+ T lymphocytes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  S. Rosenberg,et al.  Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. , 2005, Human gene therapy.

[42]  S. Rosenberg,et al.  Survival, Persistence, and Progressive Differentiation of Adoptively Transferred Tumor-Reactive T Cells Associated with Tumor Regression , 2005, Journal of immunotherapy.

[43]  A. Viola,et al.  Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers , 2005, The Journal of experimental medicine.

[44]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  N. Restifo,et al.  Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. , 2005, Current opinion in immunology.

[46]  Richard A. Morgan,et al.  Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines , 2005, The Journal of Immunology.

[47]  S. Sakaguchi.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self , 2005, Nature Immunology.

[48]  Yi Li,et al.  Directed evolution of human T-cell receptors with picomolar affinities by phage display , 2005, Nature Biotechnology.

[49]  S. Rosenberg,et al.  Bcl-2 overexpression enhances tumor-specific T-cell survival. , 2005, Cancer research.

[50]  D. Speiser,et al.  Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. , 2005, The Journal of clinical investigation.

[51]  S. Rosenberg,et al.  CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells , 2005, The Journal of Immunology.

[52]  M. Nishimura,et al.  Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. , 2005, Cancer research.

[53]  C. Klebanoff,et al.  Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. , 2005, Trends in immunology.

[54]  Pedro Romero,et al.  Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. , 2005, Immunity.

[55]  S. Rosenberg,et al.  Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. , 2005, Blood.

[56]  Mitchell Kronenberg,et al.  Toward an understanding of NKT cell biology: progress and paradoxes. , 2005, Annual review of immunology.

[57]  M. Nishimura,et al.  Simultaneous Generation of CD 8 + and CD 4 + Melanoma-Reactive T Cells by Retroviral-Mediated Transfer of a Single T-Cell Receptor , 2005 .

[58]  H. Heslop,et al.  Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease , 2004, The Journal of experimental medicine.

[59]  S. Rosenberg,et al.  Transfer Therapy Cancer Regression in Patients Receiving Cell Lymphocyte Clonotypes Correlates with Cutting Edge: Persistence of Transferred , 2022 .

[60]  C. Klebanoff,et al.  Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction1 , 2004, The Journal of Immunology.

[61]  Z. Eshhar,et al.  Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. , 2004, The Journal of clinical investigation.

[62]  F. Finkelman,et al.  Prolonged Culture of Vaccine-Primed Lymphocytes Results in Decreased Antitumor Killing and Change in Cytokine Secretion , 2004, Cancer Research.

[63]  P. Lansdorp,et al.  CD27 Expression Promotes Long-Term Survival of Functional Effector–Memory CD8+Cytotoxic T Lymphocytes in HIV-infected Patients , 2004, The Journal of experimental medicine.

[64]  Julian A. Kim,et al.  Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells , 2004, Journal of Translational Medicine.

[65]  David L. Jaye,et al.  MTA3 and the Mi-2/NuRD Complex Regulate Cell Fate during B Lymphocyte Differentiation , 2004, Cell.

[66]  S. Rutz,et al.  Interleukin‐2 is essential for CD4+CD25+ regulatory T cell function , 2004, European journal of immunology.

[67]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[68]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[69]  J. Brayer,et al.  Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses , 2004, Cancer Research.

[70]  T. Tokuhisa,et al.  Bcl6 Acts as an Amplifier for the Generation and Proliferative Capacity of Central Memory CD8+ T Cells1 , 2004, The Journal of Immunology.

[71]  P. Kourilsky,et al.  Foxp3 Expressing CD4+CD25high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells1 , 2004, The Journal of Immunology.

[72]  T. Schumacher,et al.  Tumor Rejection Induced by CD70-mediated Quantitative and Qualitative Effects on Effector CD8+ T Cell Formation , 2004, The Journal of experimental medicine.

[73]  A. Mackensen,et al.  Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. , 2004, Cancer research.

[74]  Thomas M. Schmitt,et al.  Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro , 2004, Nature Immunology.

[75]  N. Chao,et al.  Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. , 2004, Blood.

[76]  T. Waldmann,et al.  IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[77]  D. Zhou,et al.  Expression of TNFα by CD3+ and F4/80+ cells following irradiation preconditioning and allogeneic spleen cell transplantation , 2004, Bone Marrow Transplantation.

[78]  Tao Dong,et al.  Immune Activation and CD8+ T-Cell Differentiation towards Senescence in HIV-1 Infection , 2004, PLoS biology.

[79]  S. Rosenberg,et al.  Phenotypic and Functional Maturation of Tumor Antigen-Reactive CD8+ T Lymphocytes in Patients Undergoing Multiple Course Peptide Vaccination , 2004, Journal of immunotherapy.

[80]  N. Chao,et al.  Transfer of allogeneic CD 62 L memory T cells without graft-versus-host disease , 2004 .

[81]  S. Korsmeyer,et al.  Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1 , 2003, Nature.

[82]  E. Wherry,et al.  Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells , 2003, Nature Immunology.

[83]  Oreste Acuto,et al.  CD28-mediated co-stimulation: a quantitative support for TCR signalling , 2003, Nature Reviews Immunology.

[84]  J. Borst,et al.  CD27 Promotes Survival of Activated T Cells and Complements CD28 in Generation and Establishment of the Effector T Cell Pool , 2003, The Journal of experimental medicine.

[85]  S. Ziegler,et al.  Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. , 2003, The Journal of clinical investigation.

[86]  M. Schlissel,et al.  Regulating antigen-receptor gene assembly , 2003, Nature Reviews Immunology.

[87]  J. Blattman,et al.  Restoration of CD28 Expression in CD28− CD8+ Memory Effector T Cells Reconstitutes Antigen-induced IL-2 Production , 2003, The Journal of experimental medicine.

[88]  Steven A. Rosenberg,et al.  Adoptive-cell-transfer therapy for the treatment of patients with cancer , 2003, Nature Reviews Cancer.

[89]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells , 2003, The Journal of experimental medicine.

[90]  L. Naldini,et al.  Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. , 2003, Blood.

[91]  S. Rosenberg,et al.  Interleukin-2–Independent Proliferation of Human Melanoma-Reactive T Lymphocytes Transduced With an Exogenous IL-2 Gene Is Stimulation Dependent , 2003, Journal of immunotherapy.

[92]  M. Farrar,et al.  In Vivo Survival and Homeostatic Proliferation of Natural Killer Cells , 2003, The Journal of experimental medicine.

[93]  P. Burkett,et al.  Interleukin (IL)-15Rα–deficient Natural Killer Cells Survive in Normal but Not IL-15Rα–deficient Mice , 2003, The Journal of experimental medicine.

[94]  E. Field,et al.  Total lymphoid irradiation nonmyeloablative preconditioning enriches for IL-4-producing CD4+-TNK cells and skews differentiation of immunocompetent donor CD4+ cells. , 2003, Blood.

[95]  Rustom Antia,et al.  Lineage relationship and protective immunity of memory CD8 T cell subsets , 2003, Nature Immunology.

[96]  S. Ziegler,et al.  Induction of FoxP 3 and acquisition of T regulatory activity by stimulated human CD 4 + CD 25 – T cells , 2003 .

[97]  F. Sallusto,et al.  Opinion-decision making in the immune system: Progressive differentiation and selection of the fittest in the immune response , 2002, Nature Reviews Immunology.

[98]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[99]  T. Waldmann,et al.  IL-15Rα Recycles and Presents IL-15 In trans to Neighboring Cells , 2002 .

[100]  F. Marincola,et al.  Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. , 2002, Human gene therapy.

[101]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[102]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[103]  J. Lafaille,et al.  Interleukin 2 Signaling Is Required for CD4+ Regulatory T Cell Function , 2002, The Journal of experimental medicine.

[104]  R. Hodes,et al.  Telomeres in T and B cells , 2002, Nature Reviews Immunology.

[105]  R. Houghten,et al.  Degeneracy of Antigen Recognition as the Molecular Basis for the High Frequency of Naive A2/Melan-A Peptide Multimer+ CD8+ T Cells in Humans , 2002, The Journal of experimental medicine.

[106]  M. Hatano,et al.  Role for Bcl-6 in the generation and maintenance of memory CD8+ T cells , 2002, Nature Immunology.

[107]  J. Sprent,et al.  Interleukin (IL)-15 and IL-7 Jointly Regulate Homeostatic Proliferation of Memory Phenotype CD8+ Cells but Are Not Required for Memory Phenotype CD4+ Cells , 2002, The Journal of experimental medicine.

[108]  J. Sprent,et al.  Overexpression of Interleukin (IL)-7 Leads to IL-15–independent Generation of Memory Phenotype CD8+ T Cells , 2002, The Journal of experimental medicine.

[109]  Jiang Zhu,et al.  Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. , 2002, The Journal of clinical investigation.

[110]  F. Marincola,et al.  A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma , 2002, Journal of immunotherapy.

[111]  S. Carding,et al.  γδ T cells: functional plasticity and heterogeneity , 2002, Nature Reviews Immunology.

[112]  D. Richman,et al.  Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections , 2002, Nature Medicine.

[113]  J. Xiang,et al.  Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression. , 2002, Cancer research.

[114]  H. Schreiber,et al.  Immunodominance and tumor escape. , 2002, Seminars in cancer biology.

[115]  D. Fearon,et al.  Arrested Differentiation, the Self-Renewing Memory Lymphocyte, and Vaccination , 2001, Science.

[116]  G. Coukos,et al.  Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. , 2001, Cancer research.

[117]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[118]  C. Surh,et al.  Autologous Regulation of Naive T Cell Homeostasis Within the T Cell Compartment1 , 2001, The Journal of Immunology.

[119]  G. Coukos,et al.  Regulatory CD 4 1 CD 25 1 T Cells in Tumors from Patients with Early-Stage Non-Small Cell Lung Cancer and Late-Stage Ovarian Cancer 1 , 2001 .

[120]  T. Schumacher,et al.  CD27 is required for generation and long-term maintenance of T cell immunity , 2000, Nature Immunology.

[121]  S. Jameson,et al.  Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo , 2000, Nature Immunology.

[122]  Philippa Marrack,et al.  T Cells Compete for Access to Antigen-Bearing Antigen-Presenting Cells , 2000, The Journal of experimental medicine.

[123]  T. Waldmann,et al.  IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[124]  F. Sallusto,et al.  Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. , 2000, Science.

[125]  L. Bogatzki,et al.  Naive T Cells Transiently Acquire a Memory-like Phenotype during Homeostasis-Driven Proliferation , 2000, The Journal of experimental medicine.

[126]  Jianzhu Chen,et al.  Homeostasis-Stimulated Proliferation Drives Naive T Cells to Differentiate Directly into Memory T Cells , 2000, The Journal of experimental medicine.

[127]  J W Gratama,et al.  Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR , 2000, Gene Therapy.

[128]  P. Marrack,et al.  Control of homeostasis of CD8+ memory T cells by opposing cytokines. , 2000, Science.

[129]  P. Dalerba,et al.  Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[130]  M. Atkins,et al.  High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. , 2000, The cancer journal from Scientific American.

[131]  D. Speiser,et al.  High Frequencies of Naive Melan-a/Mart-1–Specific Cd8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals , 1999, The Journal of experimental medicine.

[132]  J. Sprent,et al.  The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. , 1999, Immunity.

[133]  D. Pardoll,et al.  The role of CD4+ T cell responses in antitumor immunity. , 1998, Current opinion in immunology.

[134]  J. Tschopp,et al.  Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. , 1998, Immunity.

[135]  J. Crawford,et al.  Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. , 1997, Blood.

[136]  D. Hanahan,et al.  Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy , 1997, The Journal of experimental medicine.

[137]  J. Allison,et al.  Co-stimulation in T cell responses. , 1997, Current opinion in immunology.

[138]  J. Krauss,et al.  Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. , 1996, Cancer research.

[139]  J. Bluestone,et al.  CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.

[140]  H. Schreiber,et al.  Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[141]  S. Rosenberg,et al.  Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.

[142]  John S. Thompson,et al.  Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2- incompatible transplanted SCID mice , 1994 .

[143]  Brown,et al.  Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. , 1994, Blood.

[144]  D. Hallahan,et al.  Regulation of tumor necrosis factor gene expression by ionizing radiation in human myeloid leukemia cells and peripheral blood monocytes. , 1991, The Journal of clinical investigation.

[145]  R. North.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells , 1982, The Journal of experimental medicine.

[146]  P. Greenberg,et al.  Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. , 1980, Journal of immunology.